|
Dec 27
|
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
|
|
Nov 27
|
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
|
|
Aug 30
|
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
|
|
Aug 29
|
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
|
|
Apr 27
|
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
|